专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US07412279B2 Systems and methods for targeted magnetic resonance imaging of the vascular system 失效
标题翻译：用于血管系统靶向磁共振成像的系统和方法
公开(公告)号：US07412279B2
公开(公告)日：2008-08-12
申请号：US10209416
申请日：2002-07-30
申请人： Robert M. Weisskoff , Peter D. Caravan , Sonia Witte , Randall B. Lauffer , Alan P. Carpenter, Jr.
发明人： Robert M. Weisskoff , Peter D. Caravan , Sonia Witte , Randall B. Lauffer , Alan P. Carpenter, Jr.
IPC分类号： A61B5/05
CPC分类号： A61B5/416 , A61B5/055
摘要： This invention relates to MRI-based methods and systems useful for diagnosing and clinically assessing the presence, location, and size of cardiovascular disease-associated stationary targets, e.g., thrombi and atherosclerotic lesions, within the vascular system. Methods and systems of the invention allow for improved anatomical information to be obtained from MRI images and allow the clinician to develop more effective treatment plans. In one aspect, the invention provides a method of determining the presence or absence of a stationary target within the vascular system of a mammal wherein two MRI data sets representing images of the vascular system and the stationary target are acquired after administration of a targeted MRI contrast agent. In another embodiment, both a targeted MRI contrast agent and a vascular MRI contrast agent are administered to a mammal, and both a vascular MRI and a targeted MRI data set are acquired.
摘要翻译：本发明涉及基于MRI的方法和系统，其可用于诊断和临床评估血管系统内心血管疾病相关的静止目标（例如血栓和动脉粥样硬化病变）的存在，位置和大小。本发明的方法和系统允许从MRI图像获得改进的解剖信息，并允许临床医生开发更有效的治疗计划。一方面，本发明提供一种确定哺乳动物血管系统中静止靶的存在或不存在的方法，其中在施用靶向MRI对比后获取表示血管系统和静止靶的图像的两个MRI数据集代理商在另一个实施方案中，向哺乳动物施用靶向MRI造影剂和血管MRI造影剂，并且获取血管MRI和靶向MRI数据组。

2. 发明授权

US07090828B2 Vitronectin receptor antagonist pharmaceuticals 失效
标题翻译： Vitronectin受体拮抗剂药物
公开(公告)号：US07090828B2
公开(公告)日：2006-08-15
申请号：US10348268
申请日：2003-01-21
申请人： Edward H. Cheesman , John A. Barrett , Alan P. Carpenter, Jr. , Milind Rajopadhye , Michael Sworin
发明人： Edward H. Cheesman , John A. Barrett , Alan P. Carpenter, Jr. , Milind Rajopadhye , Michael Sworin
IPC分类号： A61K5/00 , A61M36/14
CPC分类号： A61K49/0002 , A61K51/0497 , C07D401/12 , C07D401/14 , C07D403/12 , C07D403/14 , C07K5/0207 , C07K5/0806 , C07K5/0821 , C07K5/1008 , C07K5/1024 , C07K7/02 , C07K7/06 , C07K7/64 , C07K9/003
摘要： The present invention describes novel compounds of the formula: (Q)d-Ln-Ch, useful for the diagnosis and treatment of cancer, methods of imaging tumors in a patient, and methods of treating cancer in a patient. The present invention also provides novel compounds useful for monitoring therapeutic angiogenesis treatment and destruction of new angiogenic vasculature. The present invention further provides novel compounds useful for imaging atherosclerosis, restenosis, cardiac ischemia and myocardial reperfusion injury. The present invention still further provides novel compounds useful for the treatment of rheumatoid arthritis. The pharmaceuticals are comprised of a targeting moiety that binds to a receptor that is upregulated during angiogenesis, an optional linking group, and a therapeutically effective radioisotope or diagnostically effective imageable moiety. The imageable moiety is a gamma ray or positron emitting radioisotope, a magnetic resonance imaging contrast agent, an X-ray contrast agent, or an ultrasound contrast agent.
摘要翻译：本发明描述了新的下式化合物：<？in-line-formula description =“In-line Formulas”end =“lead”？>（Q）对于癌症的诊断和治疗有用的<？in-line-formula description =“在线公式”end =“tail”？>，肿瘤成像方法患者，以及在患者中治疗癌症的方法。本发明还提供了可用于监测治疗性血管生成治疗和破坏新的血管生成脉管系统的新型化合物。本发明还提供了用于成像动脉粥样硬化，再狭窄，心脏缺血和心肌再灌注损伤的新型化合物。本发明还提供了可用于治疗类风湿性关节炎的新化合物。药物由与血管发生期间上调的受体结合的靶向部分，任选的连接基团和治疗有效的放射性同位素或诊断上有效的可成像部分组成。可成像部分是伽马射线或正电子发射放射性同位素，磁共振成像造影剂，X射线造影剂或超声造影剂。

3. 发明授权

US06569402B1 Vitronectin receptor antagonist pharmaceuticals 失效
标题翻译： Vitronectin受体拮抗剂药物
公开(公告)号：US06569402B1
公开(公告)日：2003-05-27
申请号：US09599365
申请日：2000-06-21
申请人： Edward H. Cheesman , John A. Barrett , Alan P. Carpenter, Jr. , Milind Rajopadhye , Michael Sworin
发明人： Edward H. Cheesman , John A. Barrett , Alan P. Carpenter, Jr. , Milind Rajopadhye , Michael Sworin
IPC分类号： A61K500
CPC分类号： A61K49/0002 , A61K51/0497 , C07D401/12 , C07D401/14 , C07D403/12 , C07D403/14 , C07K5/0207 , C07K5/0806 , C07K5/0821 , C07K5/1008 , C07K5/1024 , C07K7/02 , C07K7/06 , C07K7/64 , C07K9/003
摘要： The present invention describes novel compounds of the formula: (Q)d—Ln—Ch, useful for the diagnosis and treatment of cancer, methods of imaging tumors in a patient, and methods of treating cancer in a patient. The present invention also provides novel compounds useful for monitoring therapeutic angiogenesis treatment and destruction of new angiogenic vasculature. The present invention further provides novel compounds useful for imaging atherosclerosis, restenosis, cardiac ischemia and myocardial reperfusion injury. The present invention still further provides novel compounds useful for the treatment of rheumatoid arthritis. The pharmaceuticals are comprised of a targeting moiety that binds to a receptor that is upregulated during angiogenesis, an optional linking group, and a therapeutically effective radioisotope or diagnostically effective imageable moiety. The imageable moiety is a gamma ray or positron emitting radioisotope, a magnetic resonance imaging contrast agent, an X-ray contrast agent, or an ultrasound contrast agent.
摘要翻译：本发明描述了新的下式化合物：可用于癌症的诊断和治疗，对患者肿瘤成像的方法，以及治疗患者癌症的方法。本发明还提供了可用于监测治疗性血管生成治疗和破坏新的血管生成脉管系统的新型化合物。本发明还提供了用于成像动脉粥样硬化，再狭窄，心脏缺血和心肌再灌注损伤的新型化合物。本发明还提供了可用于治疗类风湿性关节炎的新化合物。药物由与血管发生期间上调的受体结合的靶向部分，任选的连接基团和治疗有效的放射性同位素或诊断上有效的可成像部分组成。可成像部分是伽马射线或正电子发射放射性同位素，磁共振成像造影剂，X射线造影剂或超声造影剂。

4. 发明授权

US06511649B1 Vitronectin receptor antagonist pharmaceuticals 失效
标题翻译： Vitronectin受体拮抗剂药物
公开(公告)号：US06511649B1
公开(公告)日：2003-01-28
申请号：US09599364
申请日：2000-06-21
申请人： Thomas D. Harris , John A. Barrett , Alan P. Carpenter, Jr. , Milind Rajopadhye
发明人： Thomas D. Harris , John A. Barrett , Alan P. Carpenter, Jr. , Milind Rajopadhye
IPC分类号： A61K5100
CPC分类号： A61K49/0002 , A61K49/04 , A61K49/085 , A61K49/10 , A61K49/223 , A61K51/0455 , A61K51/0459 , A61K51/0497 , C07D401/12 , C07D401/14
摘要： The present invention describes novel compounds of the formula: (Q)d—Ln—Ch, useful for the diagnosis and treatment of cancer, methods of imaging tumors in a patient, and methods of treating cancer in a patient. The present invention also provides novel compounds useful for monitoring therapeutic angiogenesis treatment and destruction of new angiogenic vasculature. The present invention further provides novel compounds useful for imaging atherosclerosis, restenosis, cardiac ischemia, and myocardial reperfusion injury. The present invention still further provides novel compounds useful for the treatment of rheumatoid arthritis. The pharmaceuticals are comprised of a targeting moiety that binds to a receptor that is upregulated during angiogenesis, an optional linking group, and a therapeutically effective radioisotope or diagnostically effective imageable moiety. The imageable moiety is a gamma ray or positron emitting radioisotope, a magnetic resonance imaging contrast agent, an X-ray contrast agent, or an ultrasound contrast agent.
摘要翻译：本发明描述了新的下式化合物：可用于癌症的诊断和治疗，对患者肿瘤成像的方法，以及治疗患者癌症的方法。本发明还提供了可用于监测治疗性血管生成治疗和破坏新的血管生成脉管系统的新型化合物。本发明还提供可用于成像动脉粥样硬化，再狭窄，心脏缺血和心肌再灌注损伤的新型化合物。本发明还提供了可用于治疗类风湿性关节炎的新化合物。药物由与血管发生期间上调的受体结合的靶向部分，任选的连接基团和治疗有效的放射性同位素或诊断上有效的可成像部分组成。可成像部分是伽马射线或正电子发射放射性同位素，磁共振成像造影剂，X射线造影剂或超声造影剂。

5. 发明授权

US06254852B1 Porous inorganic targeted ultrasound contrast agents 失效
标题翻译：多孔无机靶向超声造影剂
公开(公告)号：US06254852B1
公开(公告)日：2001-07-03
申请号：US09356178
申请日：1999-07-16
申请人： Joseph L Glajch , Alan P. Carpenter, Jr. , Edward H. Cheesman
发明人： Joseph L Glajch , Alan P. Carpenter, Jr. , Edward H. Cheesman
IPC分类号： A61B800
CPC分类号： A61K49/225
摘要： Targeted ultrasound contrast agents are described. The contrast agents are porous particles of an inorganic material containing an entrapped gas or liquid and having an average particle diameter of about 0.05 to 500 microns. The outer surfaces of the particles incorporate a targeting ligand to target delivery of the contrast agent.
摘要翻译：描述了靶向超声造影剂。造影剂是含有截留气体或液体并且平均粒径为约0.05至500微米的无机材料的多孔颗粒。颗粒的外表面包含靶向配体以靶向造影剂的递送。

6. 发明授权

US4894445A Metal-isonitrile adducts for preparing radionuclide complexes 失效
标题翻译：用于制备放射性核素配合物的金属 - 腈腈加合物
公开(公告)号：US4894445A
公开(公告)日：1990-01-16
申请号：US880349
申请日：1986-06-25
申请人： Alan P. Carpenter, Jr. , Leo J. Maheu , Michael A. Patz , Thomas H. Tulip , Karen E. Linder , Vinayakam Subramanyam , Jeffery S. Thompson
发明人： Alan P. Carpenter, Jr. , Leo J. Maheu , Michael A. Patz , Thomas H. Tulip , Karen E. Linder , Vinayakam Subramanyam , Jeffery S. Thompson
IPC分类号： A61K51/04 , C07F1/00 , C07F11/00 , C07F15/00 , C07F15/04 , C07F15/06
CPC分类号： C07F15/065 , A61K51/0476 , C07F1/005 , C07F11/005 , C07F15/0066 , C07F15/008 , C07F15/045 , A61K2123/00
摘要： A method for preparing a coordination complex of an isonitrile ligand and a radioisotope of Tc, Ru, Co, Pt, Re, Os, Ir, W, Re, Cr, Mo, Mn, Ni, Rh, Nb and Ta from a non-radioactive metal adduct of the isonitrile.
摘要翻译：一种从非极性配位体制备异氰酸酯配体和Tc，Ru，Co，Pt，Re，Os，Ir，W，Re，Cr，Mo，Mn，Ni，Rh，Nb和Ta的放射性同位素的配位络合物的方法，异腈的放射性金属加成物。

7. 发明授权

US07138104B2 Simultaneous imaging of cardiac perfusion and a vitronectin receptor targeted imaging agent 失效
公开(公告)号：US07138104B2
公开(公告)日：2006-11-21
申请号：US10213713
申请日：2002-08-07
申请人： Alan P. Carpenter, Jr.
发明人： Alan P. Carpenter, Jr.
IPC分类号： A61B5/055
CPC分类号： A61K49/04 , A61K49/0002 , A61K49/085 , A61K49/10 , A61K49/223 , A61K51/0455 , A61K51/0459 , A61K51/0497
摘要： The present invention describes a method of concurrent imaging in a mammal comprising: a) administering to said mammal a vitronectin receptor targeted imaging agent and a perfusion imaging agent; and b) concurrently detecting the vitronectin receptor targeted imaging agent bound at the vitronectin receptor and the perfusion imaging agent; and c) forming an image from the detection of said vitronectin targeted imaging agent and said perfusion imaging agent.

8. 发明授权

US07018611B2 Vitronectin receptor antagonist pharmaceuticals 失效
标题翻译： Vitronectin受体拮抗剂药物
公开(公告)号：US07018611B2
公开(公告)日：2006-03-28
申请号：US10281015
申请日：2002-10-26
申请人： Thomas D. Harris , John A. Barrett , Alan P. Carpenter, Jr. , Milind Rajopadhye
发明人： Thomas D. Harris , John A. Barrett , Alan P. Carpenter, Jr. , Milind Rajopadhye
IPC分类号： A61K51/00 , A61M36/14
CPC分类号： A61K49/0002 , A61K49/04 , A61K49/085 , A61K49/10 , A61K49/223 , A61K51/0455 , A61K51/0459 , A61K51/0497 , C07D401/12 , C07D401/14
摘要： The present invention describes novel compounds of the formula: (Q)d—Ln—Ch, useful for the diagnosis and treatment of cancer, methods of imaging tumors in a patient, and methods of treating cancer in a patient. The present invention also provides novel compounds useful for monitoring therapeutic angiogenesis treatment and destruction of new angiogenic vasculature. The present invention further provides novel compounds useful for imaging atherosclerosis, restenosis, cardiac ischemia, and myocardial reperfusion injury. The present invention still further provides novel compounds useful for the treatment of rheumatoid arthritis. The pharmaceuticals are comprised of a targeting moiety that binds to a receptor that is upregulated during angiogenesis, an optional linking group, and a therapeutically effective radioisotope or diagnostically effective imageable moiety. The imageable moiety is a gamma ray or positron emitting radioisotope, a magnetic resonance imaging contrast agent, an X-ray contrast agent, or an ultrasound contrast agent.
摘要翻译：本发明描述了新的下式化合物：<？in-line-formula description =“In-line Formulas”end =“lead”？>（Q）对于癌症的诊断和治疗有用的<？in-line-formula description =“在线公式”end =“tail”？>，肿瘤成像方法患者，以及在患者中治疗癌症的方法。本发明还提供了可用于监测治疗性血管生成治疗和破坏新的血管生成脉管系统的新型化合物。本发明还提供可用于成像动脉粥样硬化，再狭窄，心脏缺血和心肌再灌注损伤的新型化合物。本发明还提供了可用于治疗类风湿性关节炎的新化合物。药物由与血管发生期间上调的受体结合的靶向部分，任选的连接基团和治疗有效的放射性同位素或诊断上有效的可成像部分组成。可成像部分是伽马射线或正电子发射放射性同位素，磁共振成像造影剂，X射线造影剂或超声造影剂。

9. 发明授权

US06838074B2 Simultaneous imaging of cardiac perfusion and a vitronectin receptor targeted imaging agent 失效
标题翻译：同时成像心脏灌注和玻连蛋白受体靶向成像剂
公开(公告)号：US06838074B2
公开(公告)日：2005-01-04
申请号：US10214429
申请日：2002-08-07
申请人： Alan P. Carpenter, Jr.
发明人： Alan P. Carpenter, Jr.
IPC分类号： A61K49/00
CPC分类号： A61K49/0002
摘要： The present invention describes a method of concurrent imaging in a mammal comprising: a) administering to said mammal a vitronectin receptor targeted imaging agent and a perfusion imaging agent; and b) concurrently detecting the vitronectin receptor targeted imaging agent bound at the vitronectin receptor and the perfusion imaging agent; and c) forming an image from the detection of said vitronectin targeted imaging agent and said perfusion imaging agent.
摘要翻译：本发明描述了哺乳动物同时成像的方法，包括：a）向所述哺乳动物施用玻连蛋白受体靶向成像剂和灌注成像剂; 和b）同时检测在玻连蛋白受体和灌注成像剂结合的玻连蛋白受体靶向成像剂; 和c）从所述玻连蛋白靶向成像剂和所述灌注成像剂的检测形成图像。

10. 发明授权

US07332149B1 Vitronectin receptor antagonist pharmaceuticals 失效
标题翻译： Vitronectin受体拮抗剂药物
公开(公告)号：US07332149B1
公开(公告)日：2008-02-19
申请号：US09599890
申请日：2000-06-21
申请人： Milind Rajopadhye , John A. Barrett , Alan P. Carpenter, Jr. , Edward H. Cheesman , Thomas D. Harris
发明人： Milind Rajopadhye , John A. Barrett , Alan P. Carpenter, Jr. , Edward H. Cheesman , Thomas D. Harris
IPC分类号： A61K51/00 , A61K51/04 , A61K51/06 , A61M36/00 , A61P35/00 , C07D231/54 , C07D259/00 , C07D403/14 , A61K31/416 , A61K31/33
CPC分类号： C07D401/14 , A61K49/0002 , C07D401/12 , C07K5/0205 , C07K5/0215 , C07K5/06139 , C07K5/06191
摘要： The present invention describes novel compounds of the formula: (Q)d—Ln—Ch, useful for the diagnosis and treatment of cancer, methods of imaging tumors in a patient, and methods of treating cancer in a patient. The present invention also provides novel compounds useful for monitoring therapeutic angiogenesis treatment and destruction of new angiogenic vasculature. The present invention also provides novel compounds useful for imaging atherosclerosis, restenosis, cardiac ischemia, and myocardial reperfusion injury. The present invention also provides novel compounds useful for the treatment of rheumatoid arthritis. The pharmaceuticals are comprised of a targeting moiety that binds to a receptor that is upregulated during angiogenesis, an optional linking group, and a therapeutically effective radioisotope or diagnostically effective imageable moiety. The imageable moiety is a gamma ray or positron emitting radioisotope, a magnetic resonance imaging contrast agent, an X-ray contrast agent, or an ultrasound contrast agent.
摘要翻译：本发明描述了新的下式化合物：<？in-line-formula description =“In-line Formulas”end =“lead”？>（Q）对于癌症的诊断和治疗有用的<？in-line-formula description =“在线公式”end =“tail”？>，肿瘤成像方法患者，以及在患者中治疗癌症的方法。本发明还提供了可用于监测治疗性血管生成治疗和破坏新的血管生成脉管系统的新型化合物。本发明还提供了用于成像动脉粥样硬化，再狭窄，心脏缺血和心肌再灌注损伤的新型化合物。本发明还提供了可用于治疗类风湿性关节炎的新化合物。药物由与血管发生期间上调的受体结合的靶向部分，任选的连接基团和治疗有效的放射性同位素或诊断上有效的可成像部分组成。可成像部分是伽马射线或正电子发射放射性同位素，磁共振成像造影剂，X射线造影剂或超声造影剂。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式